Pitfalls of enzyme- based diagnosis of lysosomal storage diseases in children
This study of 46 children in Egypt highlights the diagnostic limitations of relying solely on enzyme assays for lysosomal storage diseases, demonstrating that accurate diagnosis requires an integrated approach combining clinical, enzymatic, substrate, and genetic evaluations, particularly in cases where enzyme deficiency and clinical symptoms exist despite negative genetic and substrate results.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Inside every cell of the human body, tiny recycling centers work constantly to break down complex materials into simple parts the body can reuse. These centers, known as lysosomes, rely on a specific set of tools called enzymes to do their job. When one of these tools is missing or broken, the materials it is supposed to clear away begin to pile up inside the cell. This buildup acts like a clog in a drain, eventually causing the cell to malfunction and the organs it belongs to fail. This group of conditions is called lysosomal storage diseases. They are rare, inherited disorders that often strike children, leading to problems with the brain, muscles, bones, or internal organs. Because the symptoms can look like many other common illnesses, doctors often struggle to identify the exact cause. For years, the standard way to diagnose these conditions has been to measure how well the specific enzyme is working in a blood sample. If the enzyme is slow or missing, the diagnosis was often considered confirmed.
However, a new study from Egypt suggests that relying on this single test can sometimes lead doctors down the wrong path. Researchers at Damanhour Teaching Hospital examined 46 children who showed signs of these storage diseases. They did not stop at measuring the enzyme activity. Instead, they took a much broader approach, looking at the genetic code that builds the enzyme and measuring the specific waste products that should have accumulated if the disease were present. They found that while some children had low enzyme levels, their genetic code was healthy and their waste products were normal. In these cases, the low enzyme reading was a false alarm, likely caused by temporary factors or natural variations in the body, rather than a true disease. The study highlights that a diagnosis cannot be made on a single number; it requires a complete picture where the enzyme test, the genetic test, and the chemical markers all agree.
The team focused on a diverse group of children ranging from one and a half to eighteen years old, many of whom had unexplained swelling of the liver or spleen, developmental delays, or heart issues. They used advanced technology to analyze dried blood spots, measuring the activity of ten different enzymes associated with various storage diseases. Crucially, they also sequenced the genes responsible for making these enzymes and checked for the presence of specific toxic substances that build up when the enzymes fail. This multi-layered investigation allowed them to separate true cases of disease from those that only looked like disease on a surface level.
The results revealed a complex reality. Out of the 46 children, 12 were confirmed to have a lysosomal storage disease. Among these confirmed cases, the most common were disorders affecting the breakdown of complex sugars, known as mucopolysaccharidoses. These accounted for more than half of the positive diagnoses. Other confirmed cases included conditions affecting the breakdown of fats and glycogen. The researchers also identified three children who were carriers of Pompe disease, a condition that affects muscles and the heart. These children had slightly reduced enzyme levels but did not have the disease themselves, a finding that is vital for family planning and genetic counseling.
Perhaps the most significant finding involved four children who initially appeared to have a disease based on their enzyme tests. These children showed low enzyme activity, which typically signals a problem. However, when the researchers looked deeper, they found that the children's genes were normal and the toxic waste products in their blood were at healthy levels. Because the genetic code was intact and the waste products were not building up, the researchers concluded that these children did not have the disease. The low enzyme reading was a false positive. This distinction is critical because a misdiagnosis could lead to unnecessary anxiety, expensive treatments, and incorrect assumptions about a child's future health.
The study also uncovered specific patterns in the genetic mutations found in this Egyptian population. Several children with the same severe form of a storage disease shared identical genetic errors, suggesting that these specific mutations are common in the region, possibly due to families marrying within the same extended community. This finding helps explain why certain rare diseases appear more frequently in specific areas. It also points to the need for local genetic screening panels that target these common regional mutations, rather than relying only on tests designed for populations in other parts of the world.
The researchers emphasized that while enzyme testing is a useful starting point, it is not enough on its own. The study showed that a diagnosis is only secure when the enzyme test, the genetic analysis, and the measurement of waste products all point to the same conclusion. When these three pieces of evidence align, doctors can be confident in their diagnosis and can begin the appropriate treatment, which may include replacing the missing enzyme or managing the symptoms. When they do not align, as in the cases of the four children with false alarms, the diagnosis must be reconsidered.
This work underscores the importance of looking at the whole patient rather than just a single lab result. By combining different types of tests, doctors can avoid the pitfalls of false positives and ensure that children receive the correct care. The study also calls for the creation of a national registry to track these diseases in Egypt, which would help researchers understand the true scope of the problem and improve how these conditions are managed in the future. For the families involved, this integrated approach offers a clearer path forward, distinguishing between a child who needs life-changing treatment and one who is healthy despite a confusing initial test.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.